Viking Therapeutics (VKTX) Cash from Investing Activities (2016 - 2025)
Historic Cash from Investing Activities for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $160.0 million.
- Viking Therapeutics' Cash from Investing Activities rose 51783.33% to $160.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.4 million, marking a year-over-year increase of 15195.56%. This contributed to the annual value of -$553.4 million for FY2024, which is 20899.46% down from last year.
- Latest data reveals that Viking Therapeutics reported Cash from Investing Activities of $160.0 million as of Q3 2025, which was up 51783.33% from $42.5 million recorded in Q2 2025.
- Over the past 5 years, Viking Therapeutics' Cash from Investing Activities peaked at $160.0 million during Q3 2025, and registered a low of -$459.8 million during Q1 2024.
- Moreover, its 5-year median value for Cash from Investing Activities was $7.3 million (2022), whereas its average is -$19.7 million.
- Per our database at Business Quant, Viking Therapeutics' Cash from Investing Activities plummeted by 2101865.33% in 2024 and then skyrocketed by 51783.33% in 2025.
- Over the past 5 years, Viking Therapeutics' Cash from Investing Activities (Quarter) stood at $27.4 million in 2021, then plummeted by 73.51% to $7.3 million in 2022, then skyrocketed by 392.19% to $35.7 million in 2023, then crashed by 81.57% to $6.6 million in 2024, then surged by 2330.51% to $160.0 million in 2025.
- Its Cash from Investing Activities was $160.0 million in Q3 2025, compared to $42.5 million in Q2 2025 and $63.2 million in Q1 2025.